Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.37 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42019 | 1.00 | LDHA (0.37) | LDHASRRCTHHTTRAB9A | |
| SCHEMBL29973268 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| SCHEMBL6130079 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| Hydrochloric Acid SCHEMBL29059552 | 0.97 | RAB9A (0.36) | LDHASRRCTHHTTRAB9A | |
| SCHEMBL10490033 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| Ammonia Solution, Strong SCHEMBL23014704 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| SCHEMBL31553566 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| SCHEMBL3911509 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A | |
| Hydrochloric Acid SCHEMBL4920306 | 0.97 | RAB9A (0.36) | LDHASRRCTHHTTRAB9A | |
| Water SCHEMBL29364046 | 0.97 | LDHA (0.35) | LDHASRRCTHHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3804770-B1 | HYALURONIC ACID FILLER HAVING HIGH LIFT CAPACITY AND LOW INJECTION FORCE | LG CHEMICAL LTD (KR) | 2023-12-06 | — | — | EP | claimed |
| US-20140154693-A1 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-06-05 | — | — | US | claimed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | claimed |
| EP-2430195-A2 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE | Biomatrica, INC. (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2350649-A1 | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING SAME | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| EP-1482912-B1 | NALTREXONE HYDROCHLORIDE COMPOSITIONS | EURO CELTIQUE SA (LU) | 2011-05-25 | — | — | EP | claimed |
| JP-4683842-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| US-20110081363-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE | BIOMATRICA, INC. (US) | 2011-04-07 | — | — | US | claimed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | claimed |
| US-11359190-B2 | Thermolysin solution | AMANO ENZYME INC. (JP) | 2022-06-14 | — | — | US | disclosed |
| US-20210147821-A1 | THERMOLYSIN SOLUTION | AMANO ENZYME INC. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20200408787-A1 | STABILIZED QUALITY CONTROL MATERIALS FOR RED BLOOD CELLS FOR DIAGNOSTIC TESTS | NEW DIAGNOSTIC SERVICES LTD (GB) | 2020-12-31 | — | — | US | disclosed |
| EP-3663398-A1 | THERMOLYSIN SOLUTION | Amano Enzyme Inc. (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-10597640-B2 | Elution mobile phase and process for immunoaffinity chromatography of viruses | SVEUCILISTE U ZAGREBU (HR) | 2020-03-24 | — | — | US | disclosed |
| EP-0793510-A4 | METHODS FOR USE OF NOVEL LYOPROTECTANTS AND INSTANT KIT FORMULATIONS FOR RADIOPHARMACEUTICALS USING THE SAME | CYTOGEN CORP (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5738836-A | Composition for stabilizing radiolabeled organic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997037038-A1 | PROCESS FOR THE SPECIFIC MULTIPLICATION OF LONG NUCLEIC ACIDS BY PCR | BOEHRINGER MANNHEIM GMBH (DE) | 1997-10-09 | — | — | WO | disclosed |
| EP-0793510-A1 | METHODS FOR USE OF NOVEL LYOPROTECTANTS AND INSTANT KIT FORMULATIONS FOR RADIOPHARMACEUTICALS USING THE SAME | CYTOGEN CORPORATION (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996014879-A1 | METHODS FOR USE OF NOVEL LYOPROTECTANTS AND INSTANT KIT FORMULATIONS FOR RADIOPHARMACEUTICALS USING THE SAME | CYTOGEN CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5464516-A | Process for producing an electrophoresis separation layer | HYMO CORPORATION (JP) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597640-B2 | Elution mobile phase and process for immunoaffinity chromatography of viruses | ASNS, ARGLU1, PNISR | LDHA 1328/4885SRR 162/4885CTH 576/4885 |
| US-20110081363-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE | DNASE1, DIS3, NEFM | LDHA 676/4885SRR 1184/4885CTH 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.